Home > Oncology > WCLC 2018

WCLC 2018


IASLC World Conference on Lung Cancer 23-26 September 2018 Toronto, Canada

Table of Contents



Letter from the Editor

Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg

Interview with the IASCL President, Dr. Giorgio Scagliotti

Expert
Dr. Giorgio Scagliotti, University of Torino, Italy

Presidential Symposium ā€“ Top 5 abstracts

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Presented By
Dr Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, USA

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Presented By
Dr Ross Camidge, University of Colorado Cancer Center, USA

Benefits of chest CT screening

Presented By
Prof. Harry de Koning, Erasmus Medical Center, the Netherlands

New standard of care in extensive-stage small-cell lung cancer

Presented By
Dr Stephen Liu, Georgetown University Hospital, USA

No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype

Presented By
Prof. Giorgio Scagliotti, University of Turin and San Luigi Hospital, Italy

New Aspects of Immunotherapy

Next generation immunotherapy in non-small-cell lung cancer

Presented By
Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland

Combination therapies: Where are we in 2018?

Presented By
Prof. Martin Reck, German Center for Lung Research, Germany

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

Presented By
Prof. Balazs Halmos, Albert Einstein College of Medicine and Montefiore Medical Center, USA

New Aspects of Targeted Therapy

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Presented By
Prof. Suresh Ramalingam, Emory University School of Medicine, Winship Cancer Institute, USA

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma

Presented By
Dr Valerie Rusch, Dr Harvey Pass,

Angiogenic and stromal biomarkers in malignant mesothelioma

Advanced Non-small Cell Lung Cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer

Novel Therapies in ROS1 and EGFR

Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement

Central nervous system activity of ramucirumab + osimertinib in patients with advancedĀ T790M-positiveĀ EGFR-mutant non-small-cell lung cance

Entrectinib treatment in patients with ROS1+ NSCLC

Advances in Small-cell and Neuroendocrine Tumours

Small-cell lung cancer circulating tumour cell derived explants

Spread through air spaces is prognostic in lung neuroendocrine tumours

Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours

site created by:   

Ā© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com